Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review | Zendy

Fuqiang Shao | Zendy; H. Zhang | Zendy; Xiuyan Yang | Zendy; Xiaoli Luo | Zendy; Jinyi Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review

Author(s) -

Fuqiang Shao,

H. Zhang,

Xiuyan Yang,

Xiaoli Luo,

Jinyi Liu

Publication year - 2020

Publication title -

neoplasma

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.628

H-Index - 50

eISSN - 1338-4317

pISSN - 0028-2685

DOI - 10.4149/neo_2020_190801n701

Subject(s) - apatinib , medicine , adverse effect , oncology , tyrosine kinase inhibitor , vegf receptors , targeted therapy , vascular endothelial growth factor , adenocarcinoma , cancer research , cancer

Apatinib (YN968D1) is a novel and highly selective tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2) and is approved as a third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in China. Apatinib is also widely studied in other solid tumors. With the increase in clinical research of apatinib, its adverse effects have also received widespread attention. Hence, this article summarizes the pharmacological properties of apatinib and reviews its clinical use in advanced or metastatic cancers. We highlight the common adverse reactions of apatinib in clinical applications and we also clarify the corresponding prevention and intervention measures. Overall, this review will help us better understand the safety and efficacy of apatinib treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research